Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NYSE | Common Stock
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 18, 24 | 1.97 Increased by +7.65% | 1.89 Increased by +4.23% |
| Apr 23, 24 | 1.80 Increased by +5.26% | 1.69 Increased by +6.51% |
| Jan 31, 24 | 1.53 Increased by +0.66% | 1.69 Decreased by -9.47% |
| Oct 24, 23 | 1.83 Increased by +15.82% | 1.70 Increased by +7.65% |
| Jul 19, 23 | 1.83 Increased by +17.31% | 1.68 Increased by +8.93% |
| Apr 25, 23 | 1.71 Increased by +17.12% | 1.55 Increased by +10.32% |
| Jan 31, 23 | 1.52 Increased by +8.57% | 1.44 Increased by +5.56% |
| Oct 24, 22 | 1.58 Decreased by -7.60% | 1.55 Increased by +1.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 12.09 B Decreased by -5.84% | 1.76 B Increased by +11.95% | Increased by +14.56% Increased by +18.90% |
| Jun 30, 23 | 13.94 B Increased by +6.50% | 2.32 B Increased by +36.72% | Increased by +16.62% Increased by +28.37% |
| Mar 31, 23 | 13.21 B Increased by +3.07% | 2.29 B Increased by +3.20% | Increased by +17.36% Increased by +0.12% |
| Dec 31, 22 | 13.09 B Decreased by -3.22% | 1.47 B Decreased by -91.01% | Increased by +11.20% Decreased by -90.71% |
| Sep 30, 22 | 12.84 B Decreased by -3.93% | 1.57 B Decreased by -42.97% | Increased by +12.25% Decreased by -40.63% |
| Jun 30, 22 | 13.09 B Decreased by -1.57% | 1.69 B Decreased by -41.51% | Increased by +12.95% Decreased by -40.57% |
| Mar 31, 22 | 12.81 B Increased by +0.95% | 2.22 B Increased by +7.92% | Increased by +17.34% Increased by +6.91% |
| Dec 31, 21 | 13.52 B Increased by +3.78% | 16.31 B Increased by +678.80% | Increased by +120.60% Increased by +650.46% |